PMC4671814_01
Contrast-enhanced CT of the chest demonstrating the response to treatment of unresectable metastatic colorectal carcinoma.. Notes: (A) Mediastinal conglomerate mass of enlarged lymph nodes (arrow). (B) Conglomerate masses (arrow) upon initiation of dabrafenib/trametinib/oxaliplatin therapy. (C) Interval decrease in size of mediastinal nodes (arrow) after 1 month of therapy. (D) Interval resolution of mediastinal lymph nodes (arrow) after 3 months of therapy. (E) Absent mediastinal lymphadenopathy (arrow) at 6 months after therapy.
ott-8-3561Fig1.jpg
PMC4671814_01_ott-8-3561Fig1.jpg
f1-ott-8-3561
While hospitalized, the patient underwent restaging scans, which demonstrated new lymph node lesions in the anterior mediastinum as well as multiple new bilobar liver lesions consistent with progressive disease (Figures 1 and 2).
Contrast-enhanced CT of the abdomen demonstrating resolution of hepatic lesions in an unresectable metastatic colorectal carcinoma.. Notes: (A) Hepatic lesions (arrows) prior to initiation of dabrafenib/trametinib/oxaliplatin therapy. (B) Hepatic lesions (arrows) upon initiation of therapy. (C) Interval decrease in size of liver lesions (arrows) after 1 month of therapy. (D) Interval resolution of liver lesions (arrows) after 3 months of therapy. (E) Absent liver lesions (arrows) at 6 months after therapy.
ott-8-3561Fig2.jpg
PMC4671814_01_ott-8-3561Fig2.jpg
f2-ott-8-3561
While hospitalized, the patient underwent restaging scans, which demonstrated new lymph node lesions in the anterior mediastinum as well as multiple new bilobar liver lesions consistent with progressive disease (Figures 1 and 2).